Ofloxacin Sodium Chloride Injection

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

The main ingredient of this product is ofloxacin salt

This product is suitable for the following infections caused by sensitive bacteria: 1. Respiratory tract infections: acute exacerbation of chronic bronchitis, bronchiectasis with infection, acute bronchitis and pneumonia, etc. 2. Urogenital system infections: acute cystitis, acute pyelonephritis, complicated urinary tract infection, acute exacerbation of chronic urinary tract infection, acute and chronic prostatitis, and urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains), etc. 3. Gastrointestinal bacterial infections: caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Infections of the abdominal cavity, bile duct, typhoid, etc. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis. 8. Other infections, such as sinusitis, otitis media, blepharitis, etc.

Intravenous drip. Common dosage for adults: 1 Bronchial infection, lung infection: 0.3g once, twice a day, the course of treatment is 7 to 14 days. 2 Acute simple lower urinary tract infection: 0.2g once, twice a day, the course of treatment is 5 to 7 days; complicated urinary tract infection: 0.2g once, twice a day, the course of treatment is 10 to 14 days. 3 Prostatitis: 0.3g once, twice a day, the course of treatment is 6 weeks; Chlamydia cervicitis or urethritis, 0.3g once, twice a day, the course of treatment is 7 to 14 days. 4 Simple gonorrhea: 0.4g once, single dose. 5 Typhoid fever: 0.3g once, twice a day, the course of treatment is 10 to 14 days. For Pseudomonas aeruginosa infection or more severe infection, the dose can be increased to 0.4g once, twice a day.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. Occasionally may occur: 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. 2. Manifestations of interstitial nephritis such as hematuria, fever, and rash. 3. Crystalluria, more common when used in high doses. 4. Joint pain. 5. A small number of patients may experience elevated serum aminotransferases, increased blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and quinolones are contraindicated.

1 Urine alkalinizing drugs can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 Acid-reducing drugs containing aluminum or magnesium can reduce the oral absorption of this product, and it is recommended to avoid co-use. If it cannot be avoided, it should be taken 2 hours before taking this product, or 6 hours after taking the medicine. 3 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2), an increase in blood drug concentration, and the occurrence of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 4 When cyclosporine is used in combination with this product, its blood drug concentration increases, and the blood concentration of cyclosporine must be monitored and the dose adjusted. 5 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter. When used in combination, the patient's prothrombin time should be closely monitored. 6. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increase in the blood concentration of this product. 7. This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2), and may cause central nervous system toxicity.

Keep away from light and store in a sealed container.

100ml: Ofloxacin 0.2g and sodium chloride 0.9g

Heilongjiang Wusuli Jiang Pharmaceutical Co., Ltd.

• Founded in:

  1994-05-05

• Address:

  Xigang, Hulin City, Jixi City, Heilongjiang Province (Xiyuan Committee of Revolutionary Street)

• Tax NO.:

  912330036064070670

• Registered Funds:

  75 million yuan

• Website:

  Log in to view

• Email:

  Log in to view